Abstract 437P
Background
Medullary thyroid cancer (MTC) is a relatively aggressive entity with high risk of locoregional recurrence and distant metastases. There is no role for adjuvant radioactive iodine and medical treatment, while adjuvant external beam radiotherapy (EBRT) remains controversial. Guidelines and a recent systematic review suggested EBRT for extensive disease, which includes nodal involvement, extrathyroidal extension and residual disease, but data remained scarce. Toxicity of EBRT was inconsistently reported.
Methods
All consecutive patients diagnosed with MTC who received curative intent treatment from 2000 to 2018 in a tertiary institution were included. All patients received total thyroidectomy, prophylactic central compartment dissection and as-required therapeutic lateral compartments dissection. Patients at high risk of relapse (R1-2 resection, cervical lymph node metastases, extrathyroidal extension) were offered adjuvant EBRT. Radiotherapy volume covered thyroid bed and level II - VI. The whole treated volume received 60Gy with additional boost to gross residual up to 66Gy. Relapse, survival and toxicity outcomes were reported.
Results
41 patients were included, median follow-up was 12 years. Median age was 48.8, 34 (82%) patients were of pT1/2 and19 (38%) were pN1. 4 (8%) underwent R1 resection and 2 (4%) had gross residual disease despite maximal resection. 19 (46%) completed EBRT. Despite at high risk, only 3 (15.7%) had locoregional relapse after EBRT compared to 2 (9%) in those not required. Higher incidence of distant metastases in EBRT group (5 compared to 2) may reflect more advanced underlying disease. Overall survival was similar (both not yet reached median, p=0.31). Acute side effects of EBRT were well tolerated, with all patients experiencing only G1/2 mucositis and dermatitis. None required hospitalisation due to side-effects nor artificial nutrition. No G3/4 long term side-effects were observed.
Conclusions
Adjuvant EBRT in advanced MTC results in encouraging locoregional control and low incidence of significant short and long-term side-effects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Presenter: Ho Yeong Lim
Session: e-Poster Display Session
174P - A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study
Presenter: Wenwen Zhang
Session: e-Poster Display Session
175P - A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC)
Presenter: Yanhong Gu
Session: e-Poster Display Session
177P - Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC)
Presenter: Hui-Chuan Sun
Session: e-Poster Display Session
178P - Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis
Presenter: Jaekyung Cheon
Session: e-Poster Display Session
179P - Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy
Presenter: Yue Han
Session: e-Poster Display Session
180P - Real-world (RW) treatment (tx) patterns and outcomes in patients (pts) from Taiwan and Singapore with intermediate and advanced hepatocellular carcinoma (HCC)
Presenter: Su Pin Choo
Session: e-Poster Display Session
181P - Evaluation of first-line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta-analysis
Presenter: Weihua Zhi
Session: e-Poster Display Session
182P - Lenvatinib (LEN) plus anti-PD-1 antibodies vs LEN alone for advanced hepatocellular carcinoma (HCC): A real-world study
Presenter: Qi Li
Session: e-Poster Display Session